Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsLuca Fabris, MD, PhD, FAASLD
Associate Professor Adjunct of Medicine (Digestive Diseases), Internal MedicineAbout
Research
Publications
2026
Heart involvement in alcohol use disorder: observational and retrospective study in a specialized hospital unit and long-term follow-up
Vergadoro M, Zola E, Gottardi G, Di Liberto S, Frigo A, Fabris L, Simioni P. Heart involvement in alcohol use disorder: observational and retrospective study in a specialized hospital unit and long-term follow-up. Internal And Emergency Medicine 2026, 1-13. PMID: 42071131, DOI: 10.1007/s11739-026-04367-1.Peer-Reviewed Original ResearchAlcohol use disorderAlcoholic cardiomyopathy patientsAlcoholic cardiomyopathyAtrial fibrillationClinical impactInternal medicine unitsHeart failureAlcohol use disorder patientsUse disorderLong-term follow-upMedicine unitAdverse prognostic factorAlcohol-related organ damageOvert heart failureAlcohol use disorder diagnosisPrevalence of type 2 diabetesRisk of mortalityType 2 diabetesHeart involvementConsecutive patientsPrognostic factorsCardiac evaluationEchocardiographic assessmentEchocardiographic evaluationRetrospective studyEpidemiology, Risk Factors and Pathophysiology of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: An Update
Bertin L, Henderson P, Pollok R, Queiroz N, Fabris L, Savarino E, Rodríguez‐Lago I, Barberio B. Epidemiology, Risk Factors and Pathophysiology of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: An Update. 2026, 1 DOI: 10.1002/jcc5.70039.Peer-Reviewed Original ResearchPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDSclerosing cholangitisBowel diseaseRisk factorsAdvanced diseaseLiver transplantationClinical outcomesColorectal cancer incidenceBile ductInflammatory bowel disease diagnosisPathophysiology of primary sclerosing cholangitisPatients' qualityTransplant-free survivalExtensive colonic involvementNarrative review methodologyQuality of lifeInflammatory bowel disease activityCochrane Library databasesPost-transplant outcomesAssociated risk factorsSignificantly higher riskSouthern Asia regionMild clinical manifestationsWED-395-YI Extracellular matrix remodeling and gender dimorphism in the progression of primary sclerosing cholangitis to cholangiocarcinoma
Venturin C, Cadamuro M, Fiorotto R, Malouin L, Palmiotti A, Sarcognato S, Fassan M, Cillo U, Gringeri E, Mescoli C, Simioni P, Banales J, Strazzabosco M, Fabris L. WED-395-YI Extracellular matrix remodeling and gender dimorphism in the progression of primary sclerosing cholangitis to cholangiocarcinoma. Journal Of Hepatology 2026, 84: s485. DOI: 10.1016/s0168-8278(26)01422-4.Peer-Reviewed Original ResearchWED-258 Hepatic fibrosis–driven tissue factor expression by malignant cholangiocytes is associated with cancer-associated thrombosis and poor survival in intrahepatic cholangiocarcinoma
Fabris L, Herrera Y, Venturin C, Cadamuro M, Gasparello J, Radu C, Fassan M, Mescoli C, Cillo U, Gringeri E, Zanus G, Campello E, Strazzabosco M, Simioni P. WED-258 Hepatic fibrosis–driven tissue factor expression by malignant cholangiocytes is associated with cancer-associated thrombosis and poor survival in intrahepatic cholangiocarcinoma. Journal Of Hepatology 2026, 84: s466. DOI: 10.1016/s0168-8278(26)01377-2.Peer-Reviewed Original ResearchWED-379 Oncostatin M modulates tumor-stroma interactions and promotes intrahepatic cholangiocarcinoma progression via JAK/STAT signaling
Porro N, Nurcis J, De Siervi S, Turato C, Cadamuro M, Parola M, Fabris L, Pastore M, Mattei G, Magi A, Rombouts K, Cannito S, Marra F, Gentilini A. WED-379 Oncostatin M modulates tumor-stroma interactions and promotes intrahepatic cholangiocarcinoma progression via JAK/STAT signaling. Journal Of Hepatology 2026, 84: s479-s480. DOI: 10.1016/s0168-8278(26)01410-8.Peer-Reviewed Original Research
2025
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Banales J, Rodrigues P, Affò S, Andersen J, Aspichueta P, Boulter L, Bridgewater J, Calvisi D, Cardenas A, Cardinale V, Carpino G, Coulouarn C, Dopazo C, Edeline J, Fabris L, Folseraas T, Forner A, Goeppert B, Heikenwalder M, Kendall T, Khan S, Klümpen H, Koerkamp B, Lamarca A, Lindsey S, Lleo A, Luedde T, Macias R, Morement H, Nault J, Olaizola P, Perugorria M, Raggi C, Rimassa L, Saborowski A, Valle J, Vithayathil M, Vogel A, Braconi C. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nature Reviews Gastroenterology & Hepatology 2025, 23: 65-96. PMID: 41372578, DOI: 10.1038/s41575-025-01153-w.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRisk factorsOverall well-beingCurative surgical interventionInternational consensus statementPatient outcomesRare neoplasmsSurvival improvementSurgical interventionConsensus statementPoor prognosisResearch prioritiesWell-beingClinical managementPanel questionnaireBile ductConsensus recommendationsCholangiocarcinomaTherapeutic approachesEffective treatmentInternational expertsNovel biomarkersTherapeutic targetCancer-associated thrombosis in cholangiocarcinoma: Exploring a phenotype of tumor aggressiveness
Fabris L, Frión-Herrera Y, Cadamuro M, Campello E, Simioni P. Cancer-associated thrombosis in cholangiocarcinoma: Exploring a phenotype of tumor aggressiveness. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer 2025, 1880: 189457. PMID: 40987389, DOI: 10.1016/j.bbcan.2025.189457.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsVenous thromboembolismPrognostic factorsPhenotypes of tumor aggressivenessOccurrence of venous thromboembolismRisk of bleedingSubgroup of patientsCancer-associated thrombosisCancer-related morbidityLiver malignanciesTumor aggressivenessHypercoagulable stateTumor progressionWorse outcomesClinical significanceCholangiocarcinomaTreatment approachesCancer typesPrediction scoreRiskMalignancyThromboprophylaxisBleedingCase Report: jaundice in the young: the complexity of rare diseases beyond cholangiopathies
Guglielmo S, Pasin F, Biolo M, Mescoli C, Vio S, Fabris L, Simioni P. Case Report: jaundice in the young: the complexity of rare diseases beyond cholangiopathies. Frontiers In Gastroenterology 2025, 4: 1579928. PMID: 41822259, PMCID: PMC12952453, DOI: 10.3389/fgstr.2025.1579928.Peer-Reviewed Original ResearchAutoimmune hemolytic anemiaInflammatory bowel diseaseSerum IgG4 levelsAutoimmune pancreatitisCorticosteroid therapyIgG4 levelsClinical presentationAssociated with elevated serum IgG4 levelsDiagnosis of type 2 AIPComplication of autoimmune pancreatitisSuspicion of autoimmune pancreatitisElevated serum IgG4 levelsRemission of jaundiceType 2 AIPAssociated with inflammatory bowel diseaseBile duct dilatationPositive Coombs testDiagnosis of Crohn's diseaseMild weight lossPancreato-biliary diseasesPresentation of diseasePale stoolsAbdominal painClinical responseUnnecessary surgery
2024
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis
Calvaruso V, Celsa C, Cristoferi L, Scaravaglio M, Smith R, Kaur S, Di Maria G, Capodicasa L, Pennisi G, Gerussi A, Nofit E, Malinverno F, Lampertico P, Cazzagon N, Marzioni M, Vespasiani-Gentilucci U, Colapietro F, Andreone P, Lleo A, Rigamonti C, Viganò M, Giannini E, Russello M, Vanni E, Cerini F, Orlandini A, Brunetto M, Niro G, Vettori G, Castellaneta A, Cardinale V, Alvaro D, Mega A, Palitti V, Cossiga V, Morisco F, Bellanti F, Baiocchi L, Fabris L, Persico M, Degasperi E, Labanca S, Bonaiuto E, Pezzato F, Federico A, Petta S, Di Marco V, Mells G, Culver E, Invernizzi P, Cammà C, Carbone M. Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis. Clinical Gastroenterology And Hepatology 2024, 23: 1766-1775.e7. PMID: 39674236, DOI: 10.1016/j.cgh.2024.10.020.Peer-Reviewed Original ResearchConceptsCompensated advanced chronic liver diseaseClinically Significant Portal HypertensionHigh-risk varicesPrimary biliary cholangitisBaveno VIDecision curve analysisNoninvasive testsAlkaline phosphatase levelsSeverity of cholestasisBiliary cholangitisEsophageal varicesPortal hypertensionAdvanced chronic liver diseaseNoninvasive assessmentLow riskCurve analysisInfluence of cholestasisSignificant portal hypertensionAbstractText Label="Background &Alkaline phosphataseRisk of clinically significant portal hypertensionAssessment of portal hypertensionChronic liver diseaseConsecutive patientsUpper endoscopyEditor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.
Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Editor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research 2024, 84: 3909. PMID: 39544086, DOI: 10.1158/0008-5472.can-24-3017.Commentaries, Editorials and Letters